Ex vivo generation of interstitial and langerhans cell-like dendritic cell subset-based vaccines for hematological malignancies

Journal of Immunotherapy

Volumn 37, Issue 5, 2014, Pages 267-277

  Hutten, Tim ^a   Thordardottir, Soley ^a   Hobo, Willemijn ^a   Hübel, Jessica ^a   Van Der Waart, Anniek B ^a   Cany, Jeannette ^a   Dolstra, Harry ^a   Hangalapura, Basav N ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

acute myeloid leukemia; DC subsets; ex vivo; LC; umbilical cord blood

Indexed keywords

B7 ANTIGEN; CANCER VACCINE; CD34 ANTIGEN; CD40 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; FLT3 LIGAND; GLYCOPROTEIN P 15095; HLA A1 ANTIGEN; HLA A2 ANTIGEN; HLA DR ANTIGEN; INTERLEUKIN 12P40; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 6; LANGERIN; MONOCYTE DERIVED DENDRITIC CELL VACCINE; SCATTER FACTOR; T6 ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS ANTIGEN; CYTOKINE; LEUKOCYTE ANTIGEN; MINOR HISTOCOMPATIBILITY ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL EXPANSION; CELL MATURATION; CELL SUBPOPULATION; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; EX VIVO STUDY; FEMALE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LANGERHANS CELL; LEYDIG CELL; LYMPHOCYTE PROLIFERATION; MIXED LYMPHOCYTE REACTION; MONOCYTE DERIVED DENDRITIC CELL; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TH1 CELL; UMBILICAL CORD BLOOD; CELL CULTURE; CELL PROLIFERATION; HEMATOLOGIC NEOPLASMS; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; METABOLISM; MONOCYTE; PHYSIOLOGY; PROCEDURES; TRANSPLANTATION;

ANTIGENS, CD; CANCER VACCINES; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; CYTOKINES; DENDRITIC CELLS; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MINOR HISTOCOMPATIBILITY ANTIGENS; MONOCYTES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84900539900     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0000000000000035     Document Type: Article

References (60)

1. Ofran Y, Rowe JM. Induction and postremission strategies in acute myeloid leukemia: what is new? Curr Opin Hematol. 2011;18:83-88.
2. Howlader NNA, Krapcho M, Neyman N, et al. SEER Cancer Statistics Review, 1975-2008. Bethesda, MD: National Cancer Institute; 2011.
3. Kornblau SM, Covey T, Putta S, et al. Signaling changes in the stem cellfactor-AKT-S6 pathway in diagnostic AML samples are associated with disease relapse. Blood Cancer J. 2011;1:e3.
4. Van Tendeloo VF, Van de Velde A, Van Driessche A, et al. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination. Proc Natl Acad Sci USA. 2010; 107:13824-13829.
5. Ravandi F, Burnett AK, Agura ED, et al. Progress in the treatment of acute myeloid leukemia. Cancer. 2007;110: 1900-1910. (Pubitemid 350041630)
6. Soiffer RJ. Donor lymphocyte infusions for acute myeloid leukaemia. Best Pract Res Clin Haematol. 2008;21:455-466.
7. Barrett AJ, Le Blanc K. Immunotherapy prospects for acute myeloid leukaemia. Clin Exp Immunol. 2010;161:223-232.
8. Gottlieb D. Cytokine manipulation of the immune response in the treatment of human acute leukaemia. Curr Pharm Des. 2002;8:419-431. (Pubitemid 34449879)
9. Majeti R. Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells. Oncogene. 2011;30:1009-1019.
10. Ochsenreither S, Fusi A, Busse A, et al. "Wilms Tumor Protein 1" (WT1) peptide vaccination-induced complete remission in a patient with acute myeloid leukemia is accompanied by the emergence of a predominant T-cell clone both in blood and bone marrow. J Immunother. 2011;34:85-91.
11. Schmitt M, Casalegno-Garduno R, Xu X, et al. Peptide vaccines for patients with acute myeloid leukemia. Expert Rev Vaccines. 2009;8:1415-1425.
12. Smits EL, Lee C, Hardwick N, et al. Clinical evaluation of cellular immunotherapy in acute myeloid leukaemia. Cancer Immunol Immunother. 2011;6:757-769.
13. Cobb A, Roberts LK, Palucka AK, et al. Development of a HIV-1 lipopeptide antigen pulsed therapeutic dendritic cell vaccine. J Immunol Methods. 2011;365:27-37.
14. Neves AR, Ensina LF, Anselmo LB, et al. Dendritic cells derived from metastatic cancer patients vaccinated with allogeneic dendritic cell-autologous tumor cell hybrids express more CD86 and induce higher levels of interferon-gamma in mixed lymphocyte reactions. Cancer Immunol Immunother. 2005;54:61-66. (Pubitemid 40064486)
15. Ferlazzo G, Wesa A, Wei WZ, et al. Dendritic cells generated either from CD34+ progenitor cells or from monocytes differ in their ability to activate antigen-specific CD8+ T cells. J Immunol. 1999;163:3597-3604. (Pubitemid 29450879)
16. Stockinger B, Veldhoen M, Martin B. Th17 T cells: linking innate and adaptive immunity. Semin Immunol. 2007;19: 353-361. (Pubitemid 351274048)
17. Stockinger B. Th17 cells: an orphan with influence. Immunol Cell Biol. 2007;85:83-84. (Pubitemid 46398729)
18. Blom B, Ho S, Antonenko S, et al. Generation of interferon alpha-producing predendritic cell (Pre-DC)2 from human CD34(+) hematopoietic stem cells. J Exp Med. 2000;192: 1785-1796.
19. Levenga H, Schaap N, Maas F, et al. Partial T cell-depleted allogeneic stem cell transplantation following reduced-intensity conditioning creates a platform for immunotherapy with donor lymphocyte infusion and recipient dendritic cell vaccination in multiple myeloma. Biol Blood Marrow Transplant. 2010; 16:320-332.
20. Larregina AT, Falo LD Jr. Changing paradigms in cutaneous immunology: adapting with dendritic cells. J Invest Dermatol. 2005;124:1-12. (Pubitemid 40100942)
21. Klechevsky E, Morita R, Liu M, et al. Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells. Immunity. 2008;29:497-510.
22. Schweizer R, Merz K, Schlosser S, et al. Morphology and hemodynamics during vascular regeneration in critically ischemic murine skin studied by intravital microscopy techniques. Eur Surg Res. 2011;47:222-230.
23. Briley-Saebo KC, Leboeuf M, Dickson S, et al. Longitudinal tracking of human dendritic cells in murine models using magnetic resonance imaging. Magn Reson Med. 2010;64: 1510-1519.
24. Ueno H, Schmitt N, Klechevsky E, et al. Harnessing human dendritic cell subsets for medicine. Immunol Rev. 2010;234: 199-212.
25. Jongbloed SL, Kassianos AJ, McDonald KJ, et al. Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J Exp Med. 2010;207:1247-1260.
26. Ito T, Inaba M, Inaba K, et al. A CD1a+/CD11c+ subset of human blood dendritic cells is a direct precursor of Langerhans cells. J Immunol. 1999;163:1409-1419. (Pubitemid 29352761)
27. Ratzinger G, Baggers J, de Cos MA, et al. Mature human Langerhans cells derived from CD34+ hematopoietic progenitors stimulate greater cytolytic T lymphocyte activity in the absence of bioactive IL-12p70, by either single peptide presentation or cross-priming, than do dermal-interstitial or monocyte-derived dendritic cells. J Immunol. 2004;173: 2780-2791. (Pubitemid 39063140)
28. Arrighi JF, Soulas C, Hauser C, et al. TNF-alpha induces the generation of Langerin/(CD207)+ immature Langerhanstype dendritic cells from both CD14-CD1a and CD14+ CD1a-precursors derived from CD34+ cord blood cells. Eur J Immunol. 2003;33:2053-2063. (Pubitemid 37120878)
29. Bonetti MI, Pieri L, Domenici L, et al. Dendritic cells with lymphocyte-stimulating activity differentiate from human CD133 positive precursors. Blood. 2011;117:3983-3995.
30. Bontkes HJ, De Gruijl TD, Schuurhuis GJ, et al. Expansion of dendritic cell precursors from human CD34(+) progenitor cells isolated from healthy donor blood; growth factor combination determines proliferation rate and functional outcome. J Leukoc Biol. 2002;72:321-329.
31. Poulin LF, Salio M, Griessinger E, et al. Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8alpha+ dendritic cells. J Exp Med. 2010; 207:1261-1271.
32. Gatti E, Velleca MA, Biedermann BC, et al. Large-scale culture and selective maturation of human Langerhans cells from granulocyte colony-stimulating factor-mobilized CD34+ progenitors. J Immunol. 2000;164:3600-3607. (Pubitemid 30169813)
33. Fay JW, Palucka AK, Paczesny S, et al. Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34(+) progenitor-derived dendritic cells. Cancer Immunol Immunother. 2006;55: 1209-1218. (Pubitemid 43992047)
34. Muir G, Rajbabu K, Callen C, et al. Preliminary evidence that the allogeneic response might trigger antitumour immunity in patients with advanced prostate cancer. BJU Int. 2006;98: 989-995. (Pubitemid 44536446)
35. Houtenbos I, Westers TM, Ossenkoppele GJ, et al. Feasibility of clinical dendritic cell vaccination in acute myeloid leukemia. Immunobiology. 2006;211:677-685.
36. Li L, Giannopoulos K, Reinhardt P, et al. Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts. Int J Oncol. 2006;28:855-861.
37. Roddie H, Klammer M, Thomas C, et al. Phase I/II study of vaccination with dendritic-like leukaemia cells for the immunotherapy of acute myeloid leukaemia. Br J Haematol. 2006;133:152-157.
38. de Gruijl TD, van den Eertwegh AJ, Pinedo HM, et al. Wholecell cancer vaccination: from autologous to allogeneic tumorand dendritic cell-based vaccines. Cancer Immunol Immunother. 2008;57:1569-1577.
39. Palucka K, Banchereau J, Mellman I. Designing vaccines based on biology of human dendritic cell subsets. Immunity. 2010;33:464-478.
40. Salvador A, Igartua M, Pedraz JL, et al. Dendritic cells interactions with the immune system-implications for vaccine development. In: Gowder S, ed. Cell Interaction: InTech. Rijeka, Croatia: InTech Europe; 2012.
41. Valladeau J, Saeland S. Cutaneous dendritic cells. Semin Immunol. 2005;17:273-283. (Pubitemid 40984021)
42. Banchereau J, Ueno H, Dhodapkar M, et al. Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34+ progenitors and activated with type I interferon. J Immunother. 2005;28:505-516. (Pubitemid 41232572)
43. Palucka K, Ueno H, Zurawski G, et al. Building on dendritic cell subsets to improve cancer vaccines. Curr Opin Immunol. 2010;22:258-263.
44. Figdor CG, de Vries IJ, Lesterhuis WJ, et al. Dendritic cell immunotherapy: mapping the way. Nat Med. 2004;10:475-480. (Pubitemid 38667904)
45. Ludewig B, Odermatt B, Ochsenbein AF, et al. Role of dendritic cells in the induction and maintenance of autoimmune diseases. Immunol Rev. 1999;169:45-54. (Pubitemid 29338722)
46. Romano E, Rossi M, Ratzinger G, et al. Peptide-loaded Langerhans cells, despite increased IL15 secretion and T-cell activation in vitro, elicit antitumor T-cell responses comparable to peptide-loaded monocyte-derived dendritic cells in vivo. Clin Cancer Res. 2011;17:1984-1997.
47. Spanholtz J, Preijers F, Tordoir M, et al. Clinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process. PLoS One. 2011;6:e20740.
48. Hasebe H, Nagayama H, Sato K, et al. Dysfunctional regulation of the development of monocyte-derived dendritic cells in cancer patients. Biomed Pharmacother. 2000;54: 291-298.
49. Tamir A, Basagila E, Kagahzian A, et al. Induction of tumorspecific T-cell responses by vaccination with tumor lysateloaded dendritic cells in colorectal cancer patients with carcinoembryonic-antigen positive tumors. Cancer Immunol Immunother. 2007;56:2003-2016. (Pubitemid 47512607)
50. Trefzer U, Herberth G, Wohlan K, et al. Vaccination with hybrids of tumor and dendritic cells induces tumor-specific T-cell and clinical responses in melanoma stage III and IV patients. Int J Cancer. 2004;110:730-740. (Pubitemid 38746032)
51. Noirey N, Rougier N, Andre C, et al. Langerhans-like dendritic cells generated from cord blood progenitors internalize pollen allergens by macropinocytosis, and part of the molecules are processed and can activate autologous naive T lymphocytes. J Allergy Clin Immunol. 2000;105:1194-1201. (Pubitemid 30418800)
52. Nazha A, Ravandi F. Acute myeloid leukemia in the elderly: do we know who should be treated and how? Leuk Lymphoma. 2013. [Epub ahead of print].
53. Santiago-Schwarz F, Rappa DA, Laky K, et al. Stem cell factor augments tumor necrosis factor-granulocyte-macrophage colony-stimulating factor-mediated dendritic cell hematopoiesis. Stem Cells. 1995;13:186-197.
54. Liu A, Takahashi M, Narita M, et al. Generation of functional and mature dendritic cells from cord blood and bone marrow CD34+ cells by two-step culture combined with calcium ionophore treatment. J Immunol Methods. 2002;261:49-63. (Pubitemid 34175216)
55. Cullup H, Hsu AK, Kassianos AJ, et al. CD34+ cord blood DC-induced antitumor lymphoid cells have efficacy in a murine xenograft model of human ALL. J Immunother. 2011; 34:362-371.
56. Tuyaerts S, Aerts JL, Corthals J, et al. Current approaches in dendritic cell generation and future implications for cancer immunotherapy. Cancer Immunol Immunother. 2007;56: 1513-1537. (Pubitemid 47094397)
57. Frommer WB, Ludewig U, Rentsch D. Taking transgenic plants with a pinch of salt. Science. 1999;285:1222-1223. (Pubitemid 29398597)
58. Chang CC, Wright A, Punnonen J. Monocyte-derived CD1a+ and CD1a-dendritic cell subsets differ in their cytokine production profiles, susceptibilities to transfection, and capacities to direct Th cell differentiation. J Immunol. 2000;165:3584-3591. (Pubitemid 32057260)
59. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med. 1998;4:328-332. (Pubitemid 28144092)
60. Mackensen A, Drager R, Schlesier M, et al. Presence of IgE antibodies to bovine serum albumin in a patient developing anaphylaxis after vaccination with human peptide-pulsed dendritic cells. Cancer Immunol Immunother. 2000;49:152-156. (Pubitemid 30430064)